Clinical trial NCT03840005 - References

Parkinson's Disease — Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The "UP" Study

Citation(s)

•   Abbas G, Lindor KD
  Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. Expert Opin Pharmacother. 2010 Feb;11(3):387-92. doi: 10.1517/14656560903493460. Review.
•   Abdelkader NF, Safar MM, Salem HA
  Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations. Mol Neurobiol. 2016 Mar;53(2):810-817. doi: 10.1007/s12035-014-9043-8. Epub 2014 Dec 15.
•   Ackerman HD, Gerhard GS
  Bile Acids in Neurodegenerative Disorders. Front Aging Neurosci. 2016 Nov 22;8:263. eCollection 2016. Review.
•   Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, Lange SM, Anderson ML, Mahoney DW, Lindor KD
  Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol. 1999 May;30(5):830-5.
•   Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T
  Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3.
•   Auburger G, Klinkenberg M, Drost J, Marcus K, Morales-Gordo B, Kunz WS, Brandt U, Broccoli V, Reichmann H, Gispert S, Jendrach M
  Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol. 2012 Aug;46(1):20-7. doi: 10.1007/s12035-012-8245-1. Epub 2012 Feb 19. Review.
•   Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T
  Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest. 2013 Jun;123(6):2730-6.
•   Blauwendraat C, Faghri F, Pihlstrom L, Geiger JT, Elbaz A, Lesage S, Corvol JC, May P, Nicolas A, Abramzon Y, Murphy NA, Gibbs JR, Ryten M, Ferrari R, Bras J, Guerreiro R, Williams J, Sims R, Lubbe S, Hernandez DG, Mok KY, Robak L, Campbell RH, Rogaeva E, Traynor BJ, Chia R, Chung SJ; International Parkinson's Disease Genomics Consortium (IPDGC), COURAGE-PD Consortium, Hardy JA, Brice A, Wood NW, Houlden H, Shulman JM, Morris HR, Gasser T, Krüger R, Heutink P, Sharma M, Simón-Sánchez J, Nalls MA, Singleton AB, Scholz SW
  NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging. 2017 Sep;57:247.e9-247.e13. doi: 10.1016/j.neurobiolaging.2017.05.009. Epub 2017 May 17.
•   Carey EJ, Ali AH, Lindor KD
  Primary biliary cirrhosis. Lancet. 2015 Oct 17;386(10003):1565-75. doi: 10.1016/S0140-6736(15)00154-3. Epub 2015 Sep 11. Review. Erratum in: Lancet. 2015 Oct 17;386(10003):1536.
•   Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, Gama MJ
  Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. Mol Neurobiol. 2012 Oct;46(2):475-86. doi: 10.1007/s12035-012-8295-4. Epub 2012 Jul 8.
•   Chaudhuri KR, Sauerbier A, Rojo JM, Sethi K, Schapira AH, Brown RG, Antonini A, Stocchi F, Odin P, Bhattacharya K, Tsuboi Y, Abe K, Rizos A, Rodriguez-Blazquez C, Martinez-Martin P
  The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord. 2015 Mar;21(3):287-91. doi: 10.1016/j.parkreldis.2014.12.031. Epub 2015 Jan 5.
•   Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY; Parkinson Study Group Cognitive/Psychiatric Working Group
  A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord. 2010 Nov 15;25(15):2501-7. doi: 10.1002/mds.23362.
•   Chun HS, Low WC
  Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells. Toxicology. 2012 Feb 26;292(2-3):105-12. doi: 10.1016/j.tox.2011.11.020. Epub 2011 Dec 8.
•   Crosignani A, Setchell KD, Invernizzi P, Larghi A, Rodrigues CM, Podda M
  Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet. 1996 May;30(5):333-58. Review.
•   Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW
  High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol. 2008 May;48(5):792-800. doi: 10.1016/j.jhep.2007.12.023. Epub 2008 Feb 14.
•   Exner N, Lutz AK, Haass C, Winklhofer KF
  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012 Jun 26;31(14):3038-62. doi: 10.1038/emboj.2012.170. Review.
•   Findley LJ, Wood E, Lowin J, Roeder C, Bergman A, Schifflers M
  The economic burden of advanced Parkinson's disease: an analysis of a UK patient dataset. J Med Econ. 2011;14(1):130-9. doi: 10.3111/13696998.2010.551164.
•   Gasser T
  Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review. J Parkinsons Dis. 2015;5(2):209-15. doi: 10.3233/JPD-140507. Review.
•   Greene LA, Levy O, Malagelada C
  Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell Mol Neurobiol. 2011 Oct;31(7):969-78. doi: 10.1007/s10571-011-9671-8. Epub 2011 Mar 10.
•   Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D
  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009 Nov 24;73(21):1738-45. doi: 10.1212/WNL.0b013e3181c34b47.
•   Kalia LV, Lang AE
  Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19. Review.
•   Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT
  Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013 Aug;136(Pt 8):2419-31. doi: 10.1093/brain/awt192.
•   Mortiboys H, Aasly J, Bandmann O
  Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain. 2013 Oct;136(Pt 10):3038-50. doi: 10.1093/brain/awt224. Epub 2013 Sep 2.
•   Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C, Bandmann O
  UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology. 2015 Sep 8;85(10):846-52. doi: 10.1212/WNL.0000000000001905. Epub 2015 Aug 7.
•   Mortiboys H, Johansen KK, Aasly JO, Bandmann O
  Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology. 2010 Nov 30;75(22):2017-20. doi: 10.1212/WNL.0b013e3181ff9685.
•   Mortiboys H, Thomas KJ, Koopman WJ, Klaffke S, Abou-Sleiman P, Olpin S, Wood NW, Willems PH, Smeitink JA, Cookson MR, Bandmann O
  Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol. 2008 Nov;64(5):555-65. doi: 10.1002/ana.21492.
•   Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, Hubble J
  TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2006 Dec;5(12):1013-20.
•   Parry GJ, Rodrigues CM, Aranha MM, Hilbert SJ, Davey C, Kelkar P, Low WC, Steer CJ
  Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol. 2010 Jan-Feb;33(1):17-21. doi: 10.1097/WNF.0b013e3181c47569.
•   Peto V, Jenkinson C, Fitzpatrick R, Greenhall R
  The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995 Jun;4(3):241-8.
•   Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J; FRESGUN
  A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011 May;54(5):1011-9. doi: 10.1016/j.jhep.2010.08.030. Epub 2010 Oct 31.
•   Schapira AH, Olanow CW, Greenamyre JT, Bezard E
  Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet. 2014 Aug 9;384(9942):545-55. doi: 10.1016/S0140-6736(14)61010-2. Epub 2014 Jun 18. Review.
•   Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG
  Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15;22(8):1077-92.
•   Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HM
  Overcoming obstacles to repurposing for neurodegenerative disease. Ann Clin Transl Neurol. 2014 Jul;1(7):512-8. doi: 10.1002/acn3.76. Epub 2014 Jun 24.
•   Siegel JL, Jorgensen R, Angulo P, Lindor KD
  Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol. 2003 Aug;37(2):183-5.
•   Velseboer DC, de Bie RM, Wieske L, Evans JR, Mason SL, Foltynie T, Schmand B, de Haan RJ, Post B, Barker RA, Williams-Gray CH
  Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology. 2016 Mar 15;86(11):986-93. doi: 10.1212/WNL.0000000000002437. Epub 2016 Feb 17.
•   Ward A, Brogden RN, Heel RC, Speight TM, Avery GS
  Ursodeoxycholic acid: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1984 Feb;27(2):95-131. Review.

A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial To Assess The Safety And Tolerability Of 30mg/kg Daily Ursodeoxycholic Acid (UDCA) In Patients With Parkinson's Disease (PD)

Details for clinical trial NCT03840005